GET DAILY SIGNALSSurgePays (SURG) +18% Rebound: Wireless Partnerships Fuel Short-Term Recovery
Key Takeaways
- SURG shares have climbed roughly 18% over the last 30 days, rebounding from a mid-October close near $0.12 to about $0.14.
- The recovery has been driven by a series of wireless-partnership and distribution announcements, headlined by a $48 million prepaid wireless purchase commitment from Etime system.
- Despite the short-term rebound, the stock remains down roughly 50% over the last quarter, reflecting a distressed balance sheet and ongoing Nasdaq listing-compliance concerns.
- SurgePays is repositioning around its GrowthLine wireless-enablement platform and prepaid fintech services after divesting non-core assets in September 2026.
- The company remains unprofitable on a trailing basis, and its auditor has flagged going-concern uncertainty in recent filings.
Company Background and Market Position
SurgePays, Inc. is a financial technology and telecommunications company headquartered in Bartlett, Tennessee. The company operates across three segments: mobile virtual network operator (MVNO) wireless brands, a mobile virtual network enabler (MVNE) platform known as HERO, and point-of-sale and fintech services. Its business targets underserved and value-conscious consumers, with distribution through a network of more than 9,000 independent convenience stores and retail locations plus digital acquisition channels.
The company's GrowthLine platform — which opened to third-party partner brands in October 2026 — provides carrier access, billing, customer care, and compliance infrastructure to wireless brands, supporting over 200,000 subscribers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow SURG for its exposure to prepaid wireless, fintech transaction processing, and its ongoing effort to improve its balance sheet and restore Nasdaq listing compliance.
Stock Price Performance: Last 30 Days vs. the Quarter
Over the last 30 days, SURG advanced approximately 18%, rising from a closing price of $0.1196 on October 14, 2026 to $0.1413 on November 13, 2026. The move was not a straight line: shares dipped to a 52-week low of $0.1141 in mid-October before a burst of volume and a series of partnership announcements pushed the stock higher in late October and early November.
The longer view tells a different story. Over the last quarter, SURG has fallen roughly 50%, from around $0.28 in mid-August 2026 to approximately $0.14. This reflects a period of elevated volatility in August, a September slide following the company's asset divestiture, and a low-float trading environment in which the stock remains well below its 52-week high of $2.5440.
What Drove the Recent 30-Day Gains
The recent rebound has been propelled primarily by company-specific operational news rather than broad sector moves. On October 15, SurgePays announced that its GrowthLine platform had opened to partner brands, with six companies signed. On October 29, the company said it had partnered with iPMobile to bring wireless service to rural broadband providers, a deal expected to onboard more than 15 providers over 12 months.
The most significant catalyst came on November 3, when SurgePays announced a prepaid wireless agreement with Etime system committing to at least $48 million in annual prepaid wireless airtime, top-up, and refill purchase volume — roughly $4 million per month over an initial term running through September 2027. The company followed on November 13 with the launch of NILwireless, a mobile service that directs a portion of monthly plan prices to college sports programs. Rising volume around these announcements, combined with a small public float, contributed to outsized percentage moves in the stock.
Quarterly Challenges and Structural Pressures
The quarterly decline reflects deeper structural challenges rather than any single headline. In September 2026, SurgePays completed the sale of its ClearLine engagement platform, media network, and GPOX Wireless business to GPO Plus (GPOX) for $27.5 million in preferred stock, a transaction intended to strengthen stockholders' equity and address Nasdaq listing requirements, including a minimum bid-price deficiency. The market responded cautiously to the deal's structure, and the stock trended lower through September and into October.
The company also faces ongoing financial pressure. For fiscal 2025 it reported roughly $57 million in revenue against significant operating losses, and its independent auditor included a going-concern paragraph in the audit report. A June 2026 amendment with AT&T (T) that removed minimum-spend commitments and forgave approximately $10.3 million in previously billed charges provided some relief, but the stock's multi-month downtrend has persisted amid dilution from equity offerings and continued losses.
Key Factors to Watch Going Forward
Investors should monitor several factors going forward. First, the company's quarterly earnings report and updated guidance will clarify whether the recent revenue momentum and cost-structure improvements are translating into sustained profitability. Second, the execution of new agreements — including the Etime system purchase commitment and the iPMobile rural-broadband rollout — will be key tests of whether announced volumes convert into meaningful net revenue and gross profit.
Balance-sheet and listing issues remain critical. Progress on Nasdaq bid-price compliance, the pace of any future share sales under the $100 million mixed-securities shelf filed in early November, and the resolution of going-concern disclosures are all likely to influence sentiment. As with any low-priced, small-cap stock, elevated volatility and thin liquidity are material risks that investors should weigh carefully. From what I see, one thing that stands out is how execution on these partnerships could shape the next few quarters.
Using AI Tools for Deeper Market Insights
In my research on names like SURG, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum patterns across similar small-cap tech and telecom names. This helps put individual stock moves into broader context without relying solely on manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SURG's Stochastic Oscillator descends into oversold zone
The Stochastic Oscillator for SURG moved into oversold territory on November 13, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for SURG crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +7.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where SURG advanced for three days, in 203 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for SURG moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SURG as a result. In 81 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for SURG turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 42 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SURG moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SURG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SURG broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SURG entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.425) is normal, around the industry mean (2.292). P/E Ratio (-0.111) is within average values for comparable stocks, (-7.252). Projected Growth (PEG Ratio) (0.474) is also within normal values, averaging (8.005). Dividend Yield (0.000) settles around the average of (0.132) among similar stocks. P/S Ratio (0.048) is also within normal values, averaging (5.777).
The Tickeron Seasonality Score of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. SURG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SURG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What Should My First Savings Vehicle Be?
If I Want to Establish a SIMPLE IRA, Do I Have to Establish One For All Owners of My Business?
Can Blockchains Reduce Fraud and Failed Payments?
What is market breadth?
What is High-Frequency Trading (HFT), and how does it operate? Can you provide an example to illustrate its workings?
General Information
Industry MajorTelecommunications
Advertisement